Real‑world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer.

ABSTRACT: The present study aimed to assess the efficacy and safety of immune checkpoint inhibitor (ICI)-based therapy in patients with metastatic breast cancer (MBC). Therefore, eligible patients with histologically confirmed MBC, treated with ICI-based therapy, were enrolled. The primary endpoint was progression-free survival (PFS) and the secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. A total of 90 patients with MBC, treated with ICI-based therapy, with different treatment lines, were included in the present study. The median age was 50 years (range, 27-76). The predominant tumor subtypes were triple negative (53.3%) and luminal (31.1%) breast cancer. The majority of patients (61.1%) were heavily pretreated (lines of treat

SUBMITTER: Qian X 

PROVIDER: S-EPMC11542155 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature